Clinical Trial Evidence & Failure The definitive human evidence for AOD-9604 comes from a Phase 2b double-blind, placebo-controlled trial published by Stier et al
R 3 is C 2 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 4 haloalkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted C 2 -C 7 heterocycloalkyl, optionally substituted C 6 -C 10 aryl, OR 6 , NR 5 R 6 , C(O)R 7 , CO 2 R 6 , C(O)NR 5 R 6 , N(R 5 )C(O)R 7 , N(R 5 )CO 2 R 7 , NHS(O) 2 R 7 , S(O) 2 NR 5 R 6 , or R 2 and R 3 together form an optionally substituted C 2 -C 7 heterocycloalkyl ring
WADA Status: According to the World Anti-Doping Agency (WADA), all non-approved substances fall under the S0 category (Non-Approved Substances) and are prohibited in sport at all times even if they are not specifically named on the prohibited list
How to Reconstitute BPC-157: Research Guide (5mg & 10mg Vials) Introduction BPC-157 is widely studied for its effects on tendon, ligament, gut, and systemic healing
for the dual-agonist story specifically, see Semaglutide vs Tirzepatide